TY  - GEN
AU  - Novello,Silvia
AU  - Scagliotti,Giorgio
AU  - de Castro,Gilberto
AU  - Kiyik,Murat
AU  - Kowalyszyn,Rubén
AU  - Deppermann,Karl-Matthias
AU  - Arriola,Edurne
AU  - Bosquee,Lionel
AU  - Novosiadly,Ruslan D
AU  - Nguyen,Tuan S
AU  - Forest,Amelie
AU  - Tang,Shande
AU  - Kambhampati,Siva Rama Prasad
AU  - Cosaert,Jan
AU  - Reck,Martin
TI  - An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer
SN  - 1556-1380
PY  - 2017///1121
KW  - Adenocarcinoma
KW  - drug therapy
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Biomarkers, Tumor
KW  - metabolism
KW  - Carcinoma, Large Cell
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Cisplatin
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Pemetrexed
KW  - Prognosis
KW  - Survival Rate
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1016/j.jtho.2016.07.013
ER  -